Adelaide Brighton Ltd, Cover-More Group Ltd and Sigma Pharmaceutical Limited: Buy, Hold or Sell?

Should you buy, hold or sell Adelaide Brighton Ltd. (ASX:ABC), Cover-More Group Ltd (ASX:CVO) and Sigma Pharmaceutical Limited (ASX:SIP)?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The performance of the S&P/ASX 200 (Index: ^AXJO) (ASX:XJO) in 2015 was certainly disappointing for many investors as most of the top 20 shares in the index struggled to live up to expectations.

Many of the headwinds facing the big four banks, supermarket owners and miners still exist and this means 2016 could be another year for stock pickers.

It is important for investors to remember the importance of capital preservation and that it is just as important to avoid particular stocks as much as it is to buy particular stocks. Investors who bought stocks like Slater & Gordon Limited (ASX: SGH) and Dick Smith Holdings Ltd (ASX: DSH) in 2015 will have seen dramatic falls in the value of their portfolios, and in the case of Dick Smith, may have lost their capital altogether.

Looking past the top 20 stocks of the index, here are three that may interest investors in 2016:

BUY – Cover-More Group Ltd (ASX: CVO)

Cover-More specialises in the travel insurance and medical assistance markets with a growing focus on international markets. Over the last five years, the company has successfully ventured into China, India, the UK and South East Asia travel insurance markets and these segments are proving to be highly lucrative for the business.

Interestingly, Cover-More is a technologically driven company and this allows many of its products to be easily integrated into its large network of distribution partners. This also results in low capital expenditure and a scalable business model.

Despite a softer-than-expected first quarter trading update, Cover-More is still on track to deliver strong earnings growth in FY16 as a result of new contract wins, margin recovery measures and improved overseas sales.

The recent weakness in the share price has seen the company trade on a forward price-to-earnings (P/E) ratio of around 19 and it offers investors a forecast dividend yield of around 4.5%. With the growing number of tourists venturing out from Asia, Cover-More appears to be an attractive long-term value proposition.

HOLD – Adelaide Brighton Ltd. (ASX: ABC)

Adelaide Brighton is directly exposed to the economic cycle through its large operations supplying large volumes of cement, lime, concrete and other construction materials to the building and resources sectors.

Despite this, the company has done extraordinarily well to keep earnings relatively stable over the past five years with a strong uplift in earnings delivered in the first half of FY15. Underlying profit increased by 14% due to higher cement and lime volumes, improved prices and contributions from new acquisitions.

Although the company remains positive for the second half of the year, conditions in a number of its key markets remain subdued and this could begin to impact earnings over the medium term.

With the shares trading on a P/E ratio of around 15 and offering a solid dividend yield of 4.3%, there is no rush for investors to sell their holdings, but at the same time, the share price would need to be cheaper to make this stock a buy in my opinion.

SELL – Sigma Pharmaceutical Limited (ASX: SIP)

I remain bearish on Sigma and the other pharmaceutical wholesalers as ongoing cuts to PBS expenditure by the Federal Government are likely to lead to a negative impact on sales.

Sigma has been successful in offsetting these losses over recent years by reducing the discounts it offered to pharmacies but this avenue is slowly drying up as the level of discounts offered to pharmacies is now well below its peak.

In addition to this, there remains the risk that some pharmaceutical manufactures may follow Pfizer's decision to distribute their products directly to pharmacies and cut out the wholesalers altogether.

The medium and long-term future of the pharmaceutical wholesalers is unclear and I think there are better investment opportunities elsewhere.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »